Panacea Biotec Q1 results : loss at ₹15.8Cr, Revenue decreased by 10.43% YoY

Panacea Biotec Q1 Results Live : Panacea Biotec Q1 Results Live: Panacea Biotec declared their Q1 results on 14 Aug, 2024. The topline decreased by 10.43% and the loss came at ₹15.8Cr. This is a stark contrast to the same period in the previous fiscal year when the company had declared a profit of ₹10.98Cr. Compared to the previous quarter, the revenue declined by 15.2%.

The company reported a decline in Selling, General & Administrative expenses by 2.42% quarter-over-quarter (q-o-q), but saw an increase of 4.25% year-over-year (Y-o-Y). This indicates some cost control measures on a short-term basis, but an overall increase in these expenses compared to last year.

Operating income saw a significant downturn, dropping by 64.99% q-o-q and decreasing by 351.32% Y-o-Y. This substantial decline in operating income is a major factor contributing to the overall financial performance of the company for this quarter.

The earnings per share (EPS) for Q1 came in at ₹-2.88, a decrease of 150.72% Y-o-Y. This negative EPS further underscores the challenging financial situation Panacea Biotec is currently facing.

Despite the quarterly losses, Panacea Biotec has delivered a return of 21.98% in the last week and 10.65% over the last 6 months. However, the year-to-date (YTD) return stands at -2.13%, reflecting a volatile performance over the current year.

As of now, Panacea Biotec has a market capitalization of ₹1006.47 Cr. The company's 52-week high is ₹202.5, while the 52-week low is ₹112.35, indicating significant fluctuations in the stock price over the past year.